For Media: UK Press Releases

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments

Bayer receives positive CHMP opinion for acoramidis for treatment of adults with transthyretin amyloid cardiomyopathy with UK MHRA submission underway

Five crop science projects funded under Bayer – Niab Challenge Grant Program

Bayer starts Phase I study with SOS1 inhibitor in patients with advanced KRAS-mutated tumours

Bayer Launches Berocca® Mind to Support Your Memory With Spanish Sage

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months